SSAA09E2 |
| Katalog-Nr.GC62236 |
SSAA09E2 ist ein Inhibitor der SARS-CoV-Replikation (Severe Acute Respiratory Syndrome-Coronavirus), der durch Blockierung frÜher Wechselwirkungen von SARS-S mit dem Rezeptor fÜr SARS-CoV, Angiotensin Converting Enzyme-2 (ACE2) , wirkt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 883944-52-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SSAA09E2 is an inhibitor of SARS-CoV (Severe acute respiratory syndrome-Coronavirus) replication, acting by blocking early interactions of SARS-S with the receptor for SARS-CoV, Angiotensin Converting Enzyme-2 (ACE2) [1].
[1]. Bibi N, et al. Viroinformatics approach to explore the inhibitory mechanism of existing drugs repurposed to fight against COVID-19. Eur J Pharmacol. 2020;885:173496.
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *